Scholarlink

Background <p>The <i>DPM1</i> gene, crucial for glycosylation processes, has shown abnormal expression in various cancers, raising interest in its potential oncogenic role and as a biomarker in hepatocellular carcinoma (HCC).</p> Methods <p>Transcriptomic data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. <i>DPM1</i> expression levels were compared between HCC tissues and adjacent normal tissues. Clinical correlations were assessed using statistical analyses, including survival analysis and multivariate Cox regression. Immune microenvironment profiling was conducted to evaluate associations between <i>DPM1</i> expression and immune cell infiltration patterns.</p> Results <p>Elevated <i>DPM1</i> levels were associated with advanced tumor stages (<i>P</i> &lt; 0.001), higher pathologic T stage (<i>P</i> &lt; 0.001), increased histologic grade (<i>P</i> &lt; 0.001), tumor positivity (<i>P</i> &lt; 0.001), tissue inflammation (<i>P</i> &lt; 0.001), and elevated alpha-fetoprotein levels (AFP &gt; 400 ng/mL, <i>P</i> &lt; 0.05). Multivariate Cox regression analysis identified <i>DPM1</i> as an independent prognostic factor for reduced overall survival (HR = 1.990, 95% CI 1.390–2.848). Immunological analysis revealed that <i>DPM1</i> expression was positively correlated with T helper cells (<i>R</i> = 0.268, <i>P</i> &lt; 0.001) and Th2 cells (<i>R</i> = 0.295, <i>P</i> &lt; 0.001), and negatively correlated with plasmacytoid dendritic cells (<i>R</i>=-0.291, <i>P</i> &lt; 0.001) and cytotoxic cells (<i>R</i>=-0.284, <i>P</i> &lt; 0.001).</p> Conclusions <p><i>DPM1</i> serves as a promising prognostic biomarker in HCC, with its expression correlating with unfavorable clinical outcomes and immune landscape alterations. Future studies should further validate <i>DPM1</i>’s impact on ferroptosis and immune evasion in HCC, and explore its potential as a therapeutic target.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The correlation of DPM1 overexpression with immune infiltration and poor prognosis in hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Laiwei You,
  • Yang Zhou,
  • Yong Cheng,
  • Huan Wang,
  • Hao Li,
  • Jianrong Guo

摘要

Background

The DPM1 gene, crucial for glycosylation processes, has shown abnormal expression in various cancers, raising interest in its potential oncogenic role and as a biomarker in hepatocellular carcinoma (HCC).

Methods

Transcriptomic data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. DPM1 expression levels were compared between HCC tissues and adjacent normal tissues. Clinical correlations were assessed using statistical analyses, including survival analysis and multivariate Cox regression. Immune microenvironment profiling was conducted to evaluate associations between DPM1 expression and immune cell infiltration patterns.

Results

Elevated DPM1 levels were associated with advanced tumor stages (P < 0.001), higher pathologic T stage (P < 0.001), increased histologic grade (P < 0.001), tumor positivity (P < 0.001), tissue inflammation (P < 0.001), and elevated alpha-fetoprotein levels (AFP > 400 ng/mL, P < 0.05). Multivariate Cox regression analysis identified DPM1 as an independent prognostic factor for reduced overall survival (HR = 1.990, 95% CI 1.390–2.848). Immunological analysis revealed that DPM1 expression was positively correlated with T helper cells (R = 0.268, P < 0.001) and Th2 cells (R = 0.295, P < 0.001), and negatively correlated with plasmacytoid dendritic cells (R=-0.291, P < 0.001) and cytotoxic cells (R=-0.284, P < 0.001).

Conclusions

DPM1 serves as a promising prognostic biomarker in HCC, with its expression correlating with unfavorable clinical outcomes and immune landscape alterations. Future studies should further validate DPM1’s impact on ferroptosis and immune evasion in HCC, and explore its potential as a therapeutic target.